Citadel Advisors’s Chemours CC Stock Holding History

Citadel Advisors’s Portfolio CC Stock Details CC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.58M	Sell	162,500 -129,000	-44%	-$2.25M	﹤0.01%	4925
2025 Q4	$3.44M	Buy	291,500 +157,800	+118%	+$2.03M	﹤0.01%	4914
2025 Q3	$2.12M	Sell	133,700 -39,500	-23%	-$573K	﹤0.01%	5961
2025 Q2	$1.98M	Sell	173,200 -2,700	-2%	-$30.4K	﹤0.01%	5716
2025 Q1	$2.38M	Buy	175,900 +12,300	+8%	+$204K	﹤0.01%	5194
2024 Q4	$2.76M	Buy	163,600 +20,700	+14%	+$403K	﹤0.01%	4972
2024 Q3	$2.9M	Buy	142,900 +44,100	+45%	+$902K	﹤0.01%	4845
2024 Q2	$2.23M	Sell	98,800 -93,000	-48%	-$2.44M	﹤0.01%	5113
2024 Q1	$5.04M	Buy	191,800 +80,300	+72%	+$2.29M	﹤0.01%	3946
2023 Q4	$3.52M	Sell	111,500 -23,700	-18%	-$643K	﹤0.01%	4368
2023 Q3	$3.79M	Sell	135,200 -1,400	-1%	-$48.1K	﹤0.01%	4096
2023 Q2	$5.04M	Buy	136,600 +67,100	+97%	+$2.05M	﹤0.01%	3635
2023 Q1	$2.08M	Sell	69,500 -203,200	-75%	-$6.69M	﹤0.01%	5293
2022 Q4	$8.35M	Buy	272,700 +8,100	+3%	+$243K	﹤0.01%	3069
2022 Q3	$6.52M	Buy	264,600 +69,700	+36%	+$2.3M	﹤0.01%	3438
2022 Q2	$6.24M	Sell	194,900 -53,500	-22%	-$1.97M	﹤0.01%	3402
2022 Q1	$7.82M	Buy	248,400 +78,200	+46%	+$2.45M	﹤0.01%	3364
2021 Q4	$5.71M	Sell	170,200 -111,300	-40%	-$3.47M	﹤0.01%	4068
2021 Q3	$8.18M	Buy	281,500 +31,800	+13%	+$1.03M	﹤0.01%	3422
2021 Q2	$8.69M	Sell	249,700 -167,400	-40%	-$5.54M	﹤0.01%	3319
2021 Q1	$11.6M	Buy	417,100 +6,900	+2%	+$184K	﹤0.01%	2759
2020 Q4	$10.2M	Buy	410,200 +600	+0.1%	+$14.3K	﹤0.01%	2623
2020 Q3	$8.56M	Sell	409,600 -22,600	-5%	-$436K	﹤0.01%	2471
2020 Q2	$6.63M	Buy	432,200 +221,300	+105%	+$2.8M	﹤0.01%	2700
2020 Q1	$1.87M	Sell	210,900 -77,700	-27%	-$1.12M	﹤0.01%	4253
2019 Q4	$5.22M	Sell	288,600 -165,300	-36%	-$2.75M	﹤0.01%	3027
2019 Q3	$6.78M	Buy	453,900 +52,000	+13%	+$846K	﹤0.01%	2702
2019 Q2	$9.65M	Buy	401,900 +280,500	+231%	+$8.27M	﹤0.01%	2217
2019 Q1	$4.51M	Sell	121,400 -5,000	-4%	-$182K	﹤0.01%	3150
2018 Q4	$3.57M	Sell	126,400 -201,400	-61%	-$6.37M	﹤0.01%	3286
2018 Q3	$12.9M	Buy	327,800 +122,100	+59%	+$5.34M	0.01%	1818
2018 Q2	$9.13M	Buy	205,700 +78,500	+62%	+$3.91M	﹤0.01%	2037
2018 Q1	$6.2M	Buy	127,200 +3,700	+3%	+$185K	﹤0.01%	2225
2017 Q4	$6.18M	Sell	123,500 -1,800	-1%	-$94.3K	﹤0.01%	2228
2017 Q3	$6.34M	Sell	125,300 -17,800	-12%	-$840K	﹤0.01%	2043
2017 Q2	$5.43M	Buy	143,100 +101,000	+240%	+$3.98M	﹤0.01%	2038
2017 Q1	$1.62M	Buy	42,100 +6,500	+18%	+$196K	﹤0.01%	3321
2016 Q4	$786K	Buy	35,600 +19,800	+125%	+$406K	﹤0.01%	4202
2016 Q3	$253K	Sell	15,800 -26,600	-63%	-$304K	﹤0.01%	5952
2016 Q2	$349K	Buy	42,400 +10,900	+35%	+$97.1K	﹤0.01%	4994
2016 Q1	$221K	Buy	31,500 +1,200	+4%	+$6.03K	﹤0.01%	5513
2015 Q4	$162K	Buy	30,300 +5,600	+23%	+$35.8K	﹤0.01%	6086
2015 Q3	$160K	Buy	+24,700	New	+$259K	﹤0.01%	6418

Other funds holding CC

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

WHCM

Wolf Hill Capital Management Greenwich, Connecticut $1.03B AUM 80.44% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citadel Advisors's CC Position: Q1 2026 in Review

Citadel Advisors increased its Chemours (CC) stake by 161% in Q1 2026, buying an estimated $3.06M and bringing the position to 285,007 shares worth $6.28M. The position accounts for ﹤0.01% of the portfolio, ranked #3973.

Citadel Advisors first reported a position in CC in Q3 2015 and has held it in 40 quarters since. The position peaked at $67.2M in Q2 2023. 448 funds tracked by Wall St. Rank hold CC as of Q1 2026.

Citadel Advisors held 285,007 shares of Chemours worth $6.28M as of Q1 2026.
Citadel Advisors bought 175,852 Chemours shares in Q1 2026, an estimated $3.06M.
Chemours made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #3973 holding.
Citadel Advisors first reported a position in Chemours in Q3 2015 and has held it in 40 quarters since.
Citadel Advisors's Chemours position peaked at $67.2M in Q2 2023.
448 funds tracked by Wall St. Rank held Chemours as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.